ADPHEN Drug Patent Profile
✉ Email this page to a colleague
When do Adphen patents expire, and when can generic versions of Adphen launch?
Adphen is a drug marketed by Ferndale Labs and is included in one NDA.
The generic ingredient in ADPHEN is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adphen
A generic version of ADPHEN was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADPHEN?
- What are the global sales for ADPHEN?
- What is Average Wholesale Price for ADPHEN?
Summary for ADPHEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 19 |
| DailyMed Link: | ADPHEN at DailyMed |
US Patents and Regulatory Information for ADPHEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferndale Labs | ADPHEN | phendimetrazine tartrate | TABLET;ORAL | 083655-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
